Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

Pfizer Inc. ( NYSE:PFE ) will increase its dividend from last year's comparable payment on the 7th of March to ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.3 which represents a decrease of $-0.19 or -0.72% from the prior close of $26.49. The stock opened at $26.4 and touched a low of $26.22 ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...